3,4-Dihydroxymethcathinone

3,4-Dihydroxymethcathinone
Clinical data
Other names	HHMC; Dihydroxymethcathinone; 3,4-Dihydroxy-N-methylcathinone; 3,4HO-MC; 3′,4′-Hydroxy-2-(methylamino)propanophenone
Drug class	Norepinephrine–dopamine releasing agent
Identifiers
	IUPAC name 1-(3,4-dihydroxyphenyl)-2-(methylamino)propan-1-one;
CAS Number	22930-83-2;
PubChem CID	13518666;
ChemSpider	27284926;
UNII	RZR1W6RS9C;
Chemical and physical data
Formula	C10H13NO3
Molar mass	195.218 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C(=O)C1=CC(=C(C=C1)O)O)NC;
	InChI InChI=1S/C10H13NO3/c1-6(11-2)10(14)7-3-4-8(12)9(13)5-7/h3-6,11-13H,1-2H3; Key:NIRQIFAAAYJDGZ-UHFFFAOYSA-N;

3,4-Dihydroxymethcathinone (HHMC), or 3,4-dihydroxy-N-methylcathinone, is a monoamine releasing agent of the amphetamine and cathinone families. It is an active metabolite of methylone (3,4-methylenedioxymethcathinone; MDMC). The drug is a norepinephrine–dopamine releasing agent (NDRA), with EC₅₀Tooltip half-maximal effective concentration values of 110 nM for norepinephrine, 90 nM for dopamine, and 14,100 nM for serotonin in rat brain synaptosomes. HHMC was first described in the scientific literature by 2017.